Herpesvirus-encoded GPCRs: Neglected players in inflammatory and proliferative diseases?

Nature Reviews Drug Discovery

Volumn 13, Issue 2, 2014, Pages 123-139

  Vischer, Henry F ^a   Siderius, Marco ^a   Leurs, Rob ^a   Smit, Martine J ^a  

^a AMSTERDAM INSTITUTE FOR MOLECULES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIVIRAL AGENTS; CELL PROLIFERATION; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HUMANS; PROTEIN BINDING; RECEPTORS, CHEMOKINE; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TUMOR VIRUS INFECTIONS; VIRAL PROTEINS;

5 [4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDIN 1 YL] 2,2 DIPHENYLPENTANENITRILE; AROMATIC AMINE; BENZAMIDE DERIVATIVE; CHEMOKINE RECEPTOR AFFECTING AGENT; CHEMOKINE RECEPTOR ANTAGONIST; CINCHONIDINE; CINCHONINE; DIHYDROISOQUINOLINONE DERIVATIVE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR BILF1; G PROTEIN COUPLED RECEPTOR BILF1 REVERSE AGONIST; G PROTEIN COUPLED RECEPTOR BLOCKING AGENT; G PROTEIN COUPLED RECEPTOR ORF74; G PROTEIN COUPLED RECEPTOR ORF74 ANTAGONIST; G PROTEIN COUPLED RECEPTOR ORF74 REVERSE AGONIST; G PROTEIN COUPLED RECEPTOR REVERSE AGONIST AGENT; G PROTEIN COUPLED RECEPTOR U12; G PROTEIN COUPLED RECEPTOR U51; G PROTEIN COUPLED RECEPTOR UL33; G PROTEIN COUPLED RECEPTOR UL78; G PROTEIN COUPLED RECEPTOR US27; G PROTEIN COUPLED RECEPTOR US28; G PROTEIN COUPLED RECEPTOR US28 REVERSE AGONIST; INTERLEUKIN 6; PIPERAZINYLDIBENZOTHIEPIN DERIVATIVE; PROTEIN KINASE R; STAT3 PROTEIN; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BILF1 GENE; BRAIN CANCER; BURKITT LYMPHOMA; CANCER GROWTH; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; EPSTEIN BARR VIRUS; GENE FUNCTION; GENE IDENTIFICATION; GPCR GENE; HERPES VIRUS; HERPES VIRUS INFECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; IMMUNE EVASION; IMMUNOMODULATION; INFLAMMATORY DISEASE; KAPOSI SARCOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MALIGNANT NEOPLASTIC DISEASE; MONOCYTOSIS; NASOPHARYNX CARCINOMA; NONHUMAN; ONCOVIRINAE; OPEN READING FRAME; ORF74 GENE; PARACRINE SIGNALING; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; TUMOR INVASION; TUMOR VASCULARIZATION; U12 GENE; U51 GENE; UL33 GENE; UL78 GENE; US27 GENE; US28 GENE; VASCULAR DISEASE; VIRAL TROPISM; VIRUS CELL INTERACTION; VIRUS CLASSIFICATION; VIRUS GENE; VIRUS GENOME; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 84895187814     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4189     Document Type: Review

References (188)

1. Vischer, H. F., Vink, C. and Smit, M. J. A viral conspiracy: hijacking the chemokine system through virally encoded pirated chemokine receptors. Curr. Top. Microbiol. Immunol. 303, 121-154 (2006).
2. Delecluse, H. J., Feederle, R., OSullivan, B. and Taniere, P. Epstein Barr virus-associated tumours: an update for the attention of the working pathologist. J. Clin. Pathol. 60, 1358-1364 (2007).
3. Du, M. Q., Bacon, C. M. and Isaacson, P. G. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J. Clin. Pathol. 60, 1350-1357 (2007).
4. Soderberg-Naucler, C. HCMV microinfections in inflammatory diseases and cancer. J. Clin. Virol. 41, 218-223 (2008).
5. White, M. K., Gorrill, T. S. and Khalili, K. Reciprocal transactivation between HIV 1 and other human viruses. Virology 352, 1-13 (2006).
6. Fischer, S. A. Emerging viruses in transplantation: there is more to infection after transplant than CMV and EBV. Transplantation 86, 1327-1339 (2008).
7. Scholten, D. et al. Pharmacological modulation of chemokine receptor function. Br. J. Pharmacol. 165, 1617-1643 (2012).
8. Perlin, J. R. and Talbot, W. S. Signals on the move: chemokine receptors and organogenesis in zebrafish. Sci. STKE 2007, e45 (2007).
9. Lazennec, G. and Richmond, A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol. Med. 16, 133-144 (2010).
10. Wijtmans, M., Scholten, D. J., de Esch, I. J., Smit, M. J. and Leurs, R. Therapeutic targeting of chemokine receptors by small molecules. Drug Discov. Today Technol. 9, e229-e236 (2012).
11. Klarenbeek, A. et al. Targeting chemokines and chemokine receptors with antibodies. Drug Discov. Today Technol. 9, e237-e244 (2012).
12. Vischer, H. F., Leurs, R. and Smit, M. J. HCMV-encoded G protein-coupled receptors as constitutively active modulators of cellular signaling networks. Trends Pharmacol. Sci. 27, 56-63 (2006).
13. Smit, M. J. et al. Pharmacogenomic and structural analysis of constitutive G protein-coupled receptor activity. Annu. Rev. Pharmacol. Toxicol. 47, 53-87 (2007).
14. Dourmishev, L. A., Dourmishev, A. L., Palmeri, D., Schwartz, R. A. and Lukac, D. M. Molecular genetics of Kaposis sarcoma-associated herpesvirus (human herpesvirus 8) epidemiology and pathogenesis. Microbiol. Mol. Biol. Rev. 67, 175-212 (2003).
15. Cesarman, E., Chang, Y., Moore, P. S., Said, J. W. and Knowles, D. M. Kaposis sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332, 1186-1191 (1995).
16. Casper, C. and Wald, A. The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma. Curr. Top. Microbiol. Immunol. 312, 289-307 (2007).
17. Mesri, E. A., Cesarman, E. and Boshoff, C. Kaposis sarcoma and its associated herpesvirus. Nature Rev. Cancer 10, 707-719 (2010).
18. Cesarman, E. et al. Kaposis sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposis sarcoma and malignant lymphoma. J. Virol. 70, 8218-8223 (1996).
19. Arvanitakis, L., Geras-Raaka, E., Varma, A., Gershengorn, M. C. and Cesarman, E. Human herpesvirus KSHV encodes a constitutively active G protein-coupled receptor linked to cell proliferation. Nature 385, 347-350 (1997).
20. Staskus, K. A. et al. Kaposis sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J. Virol. 71, 715-719 (1997).
21. Boshoff, C. et al. Kaposis sarcoma-associated herpesvirus infects endothelial and spindle cells. Nature Med. 1, 1274-1278 (1995).
22. Bais, C. et al. G protein-coupled receptor of Kaposis sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391, 86-89 (1998).
23. Yang, T. Y. et al. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposis sarcoma. J. Exp. Med. 191, 445-454 (2000).
24. Guo, H. G. et al. Kaposis sarcoma-like tumors in a human herpesvirus 8 ORF74 transgenic mouse. J. Virol. 77, 2631-2639 (2003).
25. Montaner, S. et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposis sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3, 23-36 (2003).
26. Jensen, K. K. et al. The human herpes virus 8 encoded chemokine receptor is required for angioproliferation in a murine model of Kaposis sarcoma. J. Immunol. 174, 3686-3694 (2005).
27. Zhang, J., Wang, J., Wood, C., Xu, D. and Zhang, L. Kaposis sarcoma-associated herpesvirus/human herpesvirus 8 replication and transcription activator regulates viral and cellular genes via interferon-stimulated response elements. J. Virol. 79, 5640-5652 (2005).
28. Sandford, G., Choi, Y. B. and Nicholas, J. Role of ORF74 encoded viral G protein-coupled receptor in human herpesvirus 8 lytic replication. J. Virol. 83, 13009-13014 (2009).
29. Chiou, C. J. et al. Patterns of gene expression and a transactivation function exhibited by the vGCR (ORF74) chemokine receptor protein of Kaposis sarcoma-associated herpesvirus. J. Virol. 76, 3421-3439 (2002).
30. Montaner, S. et al. The Kaposis sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposis sarcoma. Cancer Res. 66, 168-174 (2006).
31. Glaunsinger, B. and Ganem, D. Lytic KSHV infection inhibits host gene expression by accelerating global mRNA turnover. Mol. Cell 13, 713-723 (2004).
32. Liang, Y. and Ganem, D. RBP J (CSL) is essential for activation of the K14/vGPCR promoter of Kaposis sarcoma-associated herpesvirus by the lytic switch protein RTA. J. Virol. 78, 6818-6826 (2004).
33. Cannon, M., Philpott, N. J. and Cesarman, E. The Kaposis sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells. J. Virol. 77, 57-67 (2003).
34. Verzijl, D. et al. Differential activation of murine herpesvirus 68-and Kaposis sarcoma-associated herpesvirus-encoded ORF74 G protein-coupled receptors by human and murine chemokines. J. Virol. 78, 3343-3351 (2004).
35. Gershengorn, M. C., Geras-Raaka, E., Varma, A. and Clark-Lewis, I. Chemokines activate Kaposis sarcoma-associated herpesvirus G protein-coupled receptor in mammalian cells in culture. J. Clin. Invest. 102, 1469-1472 (1998).
36. Rosenkilde, M. M., Waldhoer, M., Luttichau, H. R. and Schwartz, T. W. Virally encoded 7TM receptors. Oncogene 20, 1582-1593 (2001).
37. Kledal, T. N. et al. A broad-spectrum chemokine antagonist encoded by Kaposis sarcoma-associated herpesvirus. Science 277, 1656-1659 (1997).
38. Sodhi, A., Montaner, S. and Gutkind, J. S. Does dysregulated expression of a deregulated viral GPCR trigger Kaposis sarcomagenesis? FASEB J. 18, 422-427 (2004).
39. Yen-Moore, A. et al. Differential expression of the HHV 8 vGCR cellular homolog gene in AIDS-associated and classic Kaposis sarcoma: potential role of HIV 1 Tat. Virology 267, 247-251 (2000).
40. Sodhi, A. et al. The Kaposis sarcoma-associated herpes virus G protein-coupled receptor up regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1α. Cancer Res. 60, 4873-4880 (2000).
41. Smit, M. J. et al. Kaposis sarcoma-associated herpesvirus-encoded G protein-coupled receptor ORF74 constitutively activates p44/p42 MAPK and Akt via Gi and phospholipase C dependent signaling pathways. J. Virol. 76, 1744-1752 (2002).
42. Martin, D. et al. PI3Kγ mediates Kaposis sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. Cancer Cell 19, 805-813 (2011).
43. Bais, C. et al. Kaposis sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor 2/ KDR. Cancer Cell 3, 131-143 (2003).
44. Martin, M. J. et al. The Gα12/13 family of heterotrimeric G proteins and the small GTPase RhoA link the Kaposi sarcoma-associated herpes virus G protein-coupled receptor to heme oxygenase 1 expression and tumorigenesis. J. Biol. Chem. 282, 34510-34524 (2007).
45. Shelby, B. D. et al. Kaposis sarcoma associated herpesvirus G protein coupled receptor activation of cyclooxygenase 2 in vascular endothelial cells. Virol. J. 4, 87 (2007).
46. Sharma-Walia, N. et al. COX 2/PGE2: molecular ambassadors of Kaposis sarcoma-associated herpes virus oncoprotein-v FLIP. Oncogenesis 1, e5 (2012).
47. Montaner, S. et al. The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia. Blood 104, 2903-2911 (2004).
48. Shepard, L. W. et al. Constitutive activation of NF-κB and secretion of IL 8 induced by the G protein-coupled receptor of Kaposis sarcoma-associated herpesvirus involves Gα13 and RhoA. J. Biol. Chem. i276, 45979-45987 (2001).
49. Pati, S. et al. Activation of NF κB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposis sarcoma pathogenesis. J. Virol. 75, 8660-8673 (2001).
50. Martin, D., Galisteo, R., Ji, Y., Montaner, S. and Gutkind, J. S. An NF κB gene expression signature contributes to Kaposis sarcoma virus vGPCR-induced direct and paracrine neoplasia. Oncogene 27, 1844-1852 (2008).
51. Lei, X. et al. Regulation of NF κB inhibitor IκBα and viral replication by a KSHV microRNA. Nature Cell Biol. 12, 193-199 (2010).
52. Ma, Q. et al. Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposis sarcoma. Proc. Natl Acad. Sci. USA 106, 8683-8688 (2009).
53. Couty, J. P., Geras-Raaka, E., Weksler, B. B. and Gershengorn, M. C. Kaposis sarcoma-associated herpesvirus G protein-coupled receptor signals through multiple pathways in endothelial cells. J. Biol. Chem. 276, 33805-33811 (2001).
54. Montaner, S., Sodhi, A., Pece, S., Mesri, E. A. and Gutkind, J. S. The Kaposis sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Res. 61, 2641-2648 (2001).
55. Schwarz, M. and Murphy, P. M. Kaposis sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF κB and induces proinflammatory cytokine and chemokine production via a C terminal signaling determinant. J. Immunol. 167, 505-513 (2001).
56. Pati, S. et al. Human herpesvirus 8 encoded vGPCR activates nuclear factor of activated T cells and collaborates with human immunodeficiency virus type 1 Tat. J. Virol. 77, 5759-5773 (2003).
57. Vart, R. J. et al. Kaposis sarcoma-associated herpesvirus-encoded interleukin 6 and G protein-coupled receptor regulate angiopoietin 2 expression in lymphatic endothelial cells. Cancer Res. 67, 4042-4051 (2007).
58. Depeille, P. et al. Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptor. Clin. Cancer Res. 13, 5926-5934 (2007).
59. Jham, B. C. et al. Amplification of the angiogenic signal through the activation of the TSC/mTOR/HIF axis by the KSHV vGPCR in Kaposis sarcoma. PLoS ONE 6, e19103 (2011).
60. Lee, D. F. and Hung, M. C. All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle 6, 3011-3014 (2007).
61. Cannon, M., Cesarman, E. and Boshoff, C. K.S.H. V. G protein-coupled receptor inhibits lytic gene transcription in primary-effusion lymphoma cells via p21 mediated inhibition of Cdk2. Blood 107, 277-284 (2006).
62. Nador, R. G. et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposis sarcoma-associated herpes virus. Blood 88, 645-656 (1996).
63. Cannon, M. L. and Cesarman, E. The KSHV G protein-coupled receptor signals via multiple pathways to induce transcription factor activation in primary effusion lymphoma cells. Oncogene 23, 514-523 (2004).
64. Holst, P. J. et al. Tumorigenesis induced by the HHV8 encoded chemokine receptor requires ligand modulation of high constitutive activity. J. Clin. Invest. 108, 1789-1796 (2001).
65. Wu, B. et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066-1071 (2010).
66. Stevens, R. C. et al. The GPCR Network: a large-scale collaboration to determine human GPCR structure and function. Nature Rev. Drug Discov. 12, 25-34 (2013).
67. Chaisuparat, R. et al. Dual inhibition of PI3Kα and mTOR as an alternative treatment for Kaposis sarcoma. Cancer Res. 68, 8361-8368 (2008).
68. Cesarman, E. Gammaherpesviruses and lymphoproliferative disorders. Annu. Rev. Pathol. http://dx.doi.org/10.1146/annurev-pathol-012513-104656 (2013).
69. Humme, S. et al. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc. Natl Acad. Sci. USA 100, 10989-10994 (2003).
70. Johansen, L. M. et al. EBNA2 and activated Notch induce expression of BATF. J. Virol. 77, 6029-6040 (2003).
71. Guasparri, I., Bubman, D. and Cesarman, E. EBV LMP2A affects LMP1 mediated NF κB signaling and survival of lymphoma cells by regulating TRAF2 expression. Blood 111, 3813-3820 (2008).
72. Beisser, P. S. et al. The Epstein-Barr virus BILF1 gene encodes a G protein-coupled receptor that inhibits phosphorylation of RNA-dependent protein kinase. J. Virol. 79, 441-449 (2005).
73. Paulsen, S. J., Rosenkilde, M. M., Eugen-Olsen, J. and Kledal, T. N. Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor. J. Virol. 79, 536-546 (2005).
74. Vischer, H. F., Nijmeijer, S., Smit, M. J. and Leurs, R. Viral hijacking of human receptors through heterodimerization. Biochem. Biophys. Res. Commun. 377, 93-97 (2008).
75. Nijmeijer, S., Leurs, R., Smit, M. J. and Vischer, H. F. The Epstein-Barr virus-encoded G protein-coupled receptor BILF1 hetero-oligomerizes with human CXCR4, scavenges Gαi proteins, and constitutively impairs CXCR4 functioning. J. Biol. Chem. 285, 29632-29641 (2010).
76. Williams, B. R. PKR; a sentinel kinase for cellular stress. Oncogene 18, 6112-6120 (1999).
77. Walsh, D. and Mohr, I. Viral subversion of the host protein synthesis machinery. Nature Rev. Microbiol. 9, 860-875 (2011).
78. Griffin, B. D. et al. EBV BILF1 evolved to downregulate cell surface display of a wide range of HLA class I molecules through their cytoplasmic tail. J. Immunol. 190, 1672-1684 (2013).
79. Vuyisich, M., Spanggord, R. J. and Beal, P. A. The binding site of the RNA-dependent protein kinase (PKR) on EBER1 RNA from Epstein-Barr virus. EMBO Rep. 3, 622-627 (2002).
80. Poppers, J., Mulvey, M., Perez, C., Khoo, D. and Mohr, I. Identification of a lytic-cycle Epstein-Barr virus gene product that can regulate PKR activation. J. Virol. 77, 228-236 (2003).
81. Hislop, A. D., Taylor, G. S., Sauce, D. and Rickinson, A. B. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 25, 587-617 (2007).
82. Haque, T. et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360, 436-442 (2002).
83. Zuo, J. et al. The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways. J. Virol. 85, 1604-1614 (2011).
84. Zuo, J. et al. The Epstein-Barr virus G protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog. 5, e1000255 (2009).
85. Rowe, M. et al. Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc. Natl Acad. Sci. USA 104, 3366-3371 (2007).
86. Hislop, A. D. et al. A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J. Exp. Med. 204, 1863-1873 (2007).
87. Lyngaa, R. et al. Cell transformation mediated by the Epstein-Barr virus G protein-coupled receptor BILF1 is dependent on constitutive signaling. Oncogene 29, 4388-4398 (2010).
88. Michaelis, M., Doerr, H. W. and Cinatl, J. Jr. Oncomodulation by human cytomegalovirus: evidence becomes stronger. Med. Microbiol. Immunol. 198, 79-81 (2009).
89. Chee, M. S., Satchwell, S. C., Preddie, E., Weston, K. M. and Barrell, B. G. Human cytomegalovirus encodes three G protein-coupled receptor homologues. Nature 344, 774-777 (1990).
90. Gao, J. L. and Murphy, P. M. Human cytomegalovirus open reading frame US28 encodes a functional beta chemokine receptor. J. Biol. Chem. 269, 28539-28542 (1994).
91. Billstrom, M. A., Johnson, G. L., Avdi, N. J. and Worthen, G. S. Intracellular signaling by the chemokine receptor US28 during human cytomegalovirus infection. J. Virol. 72, 5535-5544 (1998).
92. Kledal, T. N., Rosenkilde, M. M. and Schwartz, T. W. Selective recognition of the membrane-bound CX3C chemokine, fractalkine, by the human cytomegalovirus-encoded broad-spectrum receptor US28. FEBS Lett. 441, 209-214 (1998).
93. Casarosa, P. et al. Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor US28. J. Biol. Chem. 276, 1133-1137 (2001).
94. Moepps, B. et al. Constitutive serum response factor activation by the viral chemokine receptor homologue pUS28 is differentially regulated by Gαq/11 and Gα16. Cell. Signall. 20, 1528-1537 (2008).
95. Casarosa, P. et al. Constitutive signaling of the human cytomegalovirus-encoded receptor UL33 differs from that of its rat cytomegalovirus homolog R33 by promiscuous activation of G proteins of the Gq, Gi, and Gs classes. J. Biol. Chem. 278, 50010-50023 (2003).
96. Lares, A. P., Tu, C. C. and Spencer, J. V. The human cytomegalovirus US27 gene product enhances cell proliferation and alters cellular gene expression. Virus Res. 176, 312-320 (2013).
97. Tadagaki, K. et al. Human cytomegalovirus-encoded UL33 and UL78 heteromerize with host CCR5 and CXCR4 impairing their HIV coreceptor activity. Blood 119, 4908-4918 (2012).
98. Arnolds, K. L., Lares, A. P. and Spencer, J. V. The US27 gene product of human cytomegalovirus enhances signaling of host chemokine receptor CXCR4. Virology 439, 122-131 (2013).
99. Gruijthuijsen, Y. K. et al. The rat cytomegalovirus R33 encoded G protein-coupled receptor signals in a constitutive fashion. J. Virol. 76, 1328-1338 (2002).
100. Melnychuk, R. M. et al. Mouse cytomegalovirus M33 is necessary and sufficient in virus-induced vascular smooth muscle cell migration. J. Virol. 79, 10788-10795 (2005).
101. Farrell, H. E. et al. Identification of common mechanisms by which human and mouse cytomegalovirus seven-transmembrane receptor homologues contribute to in vivo phenotypes in a mouse model. J. Virol. 87, 4112-4117 (2013).
102. Farrell, H. E. et al. Partial functional complementation between human and mouse cytomegalovirus chemokine receptor homologues. J. Virol. 85, 6091-6095 (2011).
103. Margulies, B. J., Browne, H. and Gibson, W. Identification of the human cytomegalovirus G protein-coupled receptor homologue encoded by UL33 in infected cells and enveloped virus particles. Virology 225, 111-125 (1996).
104. Fraile-Ramos, A. et al. The human cytomegalovirus US28 protein is located in endocytic vesicles and undergoes constitutive endocytosis and recycling. Mol. Biol. Cell 12, 1737-1749 (2001).
105. Margulies, B. J. and Gibson, W. The chemokine receptor homologue encoded by US27 of human cytomegalovirus is heavily glycosylated and is present in infected human foreskin fibroblasts and enveloped virus particles. Virus Res. 123, 57-71 (2007).
106. Penfold, M. E., Schmidt, T. L., Dairaghi, D. J., Barry, P. A. and Schall, T. J. Characterization of the rhesus cytomegalovirus US28 locus. J. Virol. 77, 10404-10413 (2003).
107. Varnum, S. M. et al. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J. Virol. 78, 10960-10966 (2004).
108. OConnor, C. M. and Shenk, T. Human cytomegalovirus pUS27 G protein-coupled receptor homologue is required for efficient spread by the extracellular route but not for direct cell to cell spread. J. Virol. 85, 3700-3707 (2011).
109. Rowe, W. P., Hartley, J. W., Cramblett, H. G. and Mastrota, F. M. Detection of human salivary gland virus in the mouth and urine of children. Am. J. Hyg. 67, 57-65 (1958).
110. Beisser, P. S. et al. The R33 G protein-coupled receptor gene of rat cytomegalovirus plays an essential role in the pathogenesis of viral infection. J. Virol. 72, 2352-2363 (1998).
111. Davis-Poynter, N. J. et al. Identification and characterization of a G protein-coupled receptor homolog encoded by murine cytomegalovirus. J. Virol. 71, 1521-1529 (1997).
112. Case, R. et al. Functional analysis of the murine cytomegalovirus chemokine receptor homologue M33: ablation of constitutive signaling is associated with an attenuated phenotype in vivo. J. Virol. 82, 1884-1898 (2008).
113. Cardin, R. D., Schaefer, G. C., Allen, J. R., Davis-Poynter, N. J. and Farrell, H. E. The M33 chemokine receptor homolog of murine cytomegalovirus exhibits a differential tissue-specific role during in vivo replication and latency. J. Virol. 83, 7590-7601 (2009).
114. Streblow, D. N. et al. Rat cytomegalovirus-accelerated transplant vascular sclerosis is reduced with mutation of the chemokine-receptor R33. Am. J. Transplant. 5, 436-442 (2005).
115. Oliveira, S. A. and Shenk, T. E. Murine cytomegalovirus M78 protein, a G protein-coupled receptor homologue, is a constituent of the virion and facilitates accumulation of immediate-early viral mRNA. Proc. Natl Acad. Sci. USA 98, 3237-3242 (2001).
116. Beisser, P. S., Grauls, G., Bruggeman, C. A. and Vink, C. Deletion of the R78 G protein-coupled receptor gene from rat cytomegalovirus results in an attenuated, syncytium-inducing mutant strain. J. Virol. 73, 7218-7230 (1999).
117. Kaptein, S. J. et al. The rat cytomegalovirus R78 G protein-coupled receptor gene is required for production of infectious virus in the spleen. J. Gen. Virol. 84, 2517-2530 (2003).
118. Michel, D. et al. The human cytomegalovirus UL78 gene is highly conserved among clinical isolates, but is dispensable for replication in fibroblasts and a renal artery organ-culture system. J. Gen. Virol. 86, 297-306 (2005).
119. OConnor, C. M. and Shenk, T. Human cytomegalovirus pUL78 G protein-coupled receptor homologue is required for timely cell entry in epithelial cells but not fibroblasts. J. Virol. 86, 11425-11433 (2012).
120. Tschische, P., Tadagaki, K., Kamal, M., Jockers, R. and Waldhoer, M. Heteromerization of human cytomegalovirus encoded chemokine receptors. Biochem. Pharmacol. 82, 610-619 (2011).
121. Kuhn, D. E., Beall, C. J. and Kolattukudy, P. E. The cytomegalovirus US28 protein binds multiple CC chemokines with high affinity. Biochem. Biophys. Res. Commun. 211, 325-330 (1995).
122. Casarosa, P. et al. CC and CX3C chemokines differentially interact with the N terminus of the human cytomegalovirus-encoded US28 receptor. J. Biol. Chem. 280, 3275-3285 (2005).
123. Mokros, T. et al. Surface expression and endocytosis of the human cytomegalovirus-encoded chemokine receptor US28 is regulated by agonist-independent phosphorylation. J. Biol. Chem. 277, 45122-45128 (2002).
124. Miller, W. E., Houtz, D. A., Nelson, C. D., Kolattukudy, P. E. and Lefkowitz, R. J. G protein-coupled receptor (GPCR) kinase phosphorylation and beta-arrestin recruitment regulate the constitutive signaling activity of the human cytomegalovirus US28 GPCR. J. Biol. Chem. 278, 21663-21671 (2003).
125. Droese, J. et al. HCMV-encoded chemokine receptor US28 employs multiple routes for internalization. Biochem. Biophys. Res. Commun. 322, 42-49 (2004).
126. Bodaghi, B. et al. Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells. J. Exp. Med. 188, 855-866 (1998).
127. Vieira, J., Schall, T. J., Corey, L. and Geballe, A. P. Functional analysis of the human cytomegalovirus US28 gene by insertion mutagenesis with the green fluorescent protein gene. J. Virol. 72, 8158-8165 (1998).
128. Billstrom, M. A., Lehman, L. A. and Scott Worthen, G. Depletion of extracellular RANTES during human cytomegalovirus infection of endothelial cells. Am. J. Respir. Cell. Mol. Biol. 21, 163-167 (1999).
129. Casarosa, P. et al. Identification of the first nonpeptidergic inverse agonist for a constitutively active viral-encoded G protein-coupled receptor. J. Biol. Chem. 278, 5172-5178 (2003).
130. Hulshof, J. W. et al. Synthesis and structure-activity relationship of the first nonpeptidergic inverse agonists for the human cytomegalovirus encoded chemokine receptor US28. J. Med. Chem. 48, 6461-6471 (2005).
131. Hulshof, J. W. et al. Synthesis and pharmacological characterization of novel inverse agonists acting on the viral-encoded chemokine receptor US28. Bioorg. Med. Chem. 14, 7213-7230 (2006).
132. Vischer, H. F. et al. Identification of novel allosteric nonpeptidergic inhibitors of the human cytomegalovirus-encoded chemokine receptor US28. Bioorg. Med. Chem. 18, 675-688 (2010).
133. Frascaroli, G. et al. Human cytomegalovirus subverts the functions of monocytes, impairing chemokine-mediated migration and leukocyte recruitment. J. Virol. 80, 7578-7589 (2006).
134. King, C. A., Baillie, J. and Sinclair, J. H. Human cytomegalovirus modulation of CCR5 expression on myeloid cells affects susceptibility to human immunodeficiency virus type 1 infection. J. Gen. Virol. 87, 2171-2180 (2006).
135. Cobbs, C. S. et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 62, 3347-3350 (2002).
136. Miller, W. E. et al. US28 is a potent activator of phospholipase C during HCMV infection of clinically relevant target cells. PLoS ONE 7, e50524 (2012).
137. Scheurer, M. E., Bondy, M. L., Aldape, K. D., Albrecht, T. and El Zein, R. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol. 116, 79-86 (2008).
138. Bhattacharjee, B., Renzette, N. and Kowalik, T. F. Genetic analysis of cytomegalovirus in malignant gliomas. J. Virol. 86, 6815-6824 (2012).
139. Baryawno, N. et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J. Clin. Invest. 121, 4043-4055 (2011).
140. Wolmer-Solberg, N. et al. Frequent detection of human cytomegalovirus in neuroblastoma: a novel therapeutic target? Int. J. Cancer 133, 2351-2361(2013).
141. Wang, X., Huang, D. Y., Huong, S. M. and Huang, E. S. Integrin αβ3 is a coreceptor for human cytomegalovirus. Nature Med. 11, 515-521 (2005).
142. Wang, X., Huong, S. M., Chiu, M. L., Raab-Traub, N. and Huang, E. S. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 424, 456-461 (2003).
143. Soroceanu, L., Akhavan, A. and Cobbs, C. S. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 455, 391-395 (2008).
144. Hanahan, D. and Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
145. Zhu, H., Cong, J. P., Mamtora, G., Gingeras, T. and Shenk, T. Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays. Proc. Natl Acad. Sci. USA 95, 14470-14475 (1998).
146. Soroceanu, L. et al. Human cytomegalovirus US28 found in glioblastoma promotes an invasive and angiogenic phenotype. Cancer Res. 71, 6643-6653 (2011).
147. Maussang, D. et al. Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. Proc. Natl Acad. Sci. USA 103, 13068-13073 (2006).
148. Maussang, D. et al. The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase 2. Cancer Res. 69, 2861-2869 (2009).
149. Turini, M. E. and DuBois, R. N. Cyclooxygenase 2: a therapeutic target. Annu. Rev. Med. 53, 35-57 (2002).
150. Dziurzynski, K. et al. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. 14, 246-255 (2012).
151. Soderberg-Naucler, C., Rahbar, A. and Stragliotto, G. Survival in patients with glioblastoma receiving valganciclovir. N. Engl. J. Med. 369, 985-986 (2013).
152. Price, R. L. et al. Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. Cancer Res. 73, 3441-3450 (2013).
153. Dziurzynski, K. et al. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin. Cancer Res. 17, 4642-4649 (2011).
154. Slinger, E. et al. HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL 6-STAT3 axis. Sci. Signal. 3, ra58 (2010).
155. Wang, H. et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 27, 2393-2404 (2009).
156. Aaronson, D. S. et al. An androgen-IL 6-Stat3 autocrine loop re routes EGF signal in prostate cancer cells. Mol. Cell Endocrinol. 270, 50-56 (2007).
157. Lieblein, J. C. et al. STAT3 can be activated through paracrine signaling in breast epithelial cells. BMC Cancer 8, 302 (2008).
158. Botto, S. et al. IL 6 in human cytomegalovirus secretome promotes angiogenesis and survival of endothelial cells through the stimulation of survivin. Blood 117, 352-361 (2011).
159. Martini, M. et al. Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int. J. Cancer 123, 2955-2960 (2008).
160. Desbaillets, I. et al. Human astrocytomas and glioblastomas express monocyte chemoattractant protein 1 (MCP 1) in vivo and in vitro. Int. J. Cancer 58, 240-247 (1994).
161. Harkins, L. et al. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 360, 1557-1563 (2002).
162. Chen, H. P. et al. Human cytomegalovirus preferentially infects the neoplastic epithelium of colorectal cancer: a quantitative and histological analysis. J. Clin. Virol. 54, 240-244 (2012).
163. Bongers, G. et al. The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. J. Clin. Invest. 120, 3969-3978 (2010).
164. Mazzucchelli, L. et al. Differential in situ expression of the genes encoding the chemokines MCP 1 and RANTES in human inflammatory bowel disease. J. Pathol. 178, 201-206 (1996).
165. Bakker, R. A., Casarosa, P., Timmerman, H., Smit, M. J. and Leurs, R. Constitutively active Gq/11 coupled receptors enable signaling by co expressed Gi/o coupled receptors. J. Biol. Chem. 279, 5152-5161 (2004).
166. Langemeijer, E. V. et al. Constitutive beta-catenin signaling by the viral chemokine receptor US28. PloS one 7, e48935 (2012).
167. Ullman, T., Croog, V., Harpaz, N., Sachar, D. and Itzkowitz, S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 125, 1311-1319 (2003).
168. Bongers, G. et al. A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans. Gastroenterology 143, 730-740 (2012).
169. Speir, E. et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 265, 391-394 (1994).
170. Melnick, J. L., Adam, E. and DeBakey, M. E. Cytomegalovirus and atherosclerosis. Arch. Immunol. Ther. Exp. 44, 297-302 (1996).
171. Caposio, P., Orloff, S. L. and Streblow, D. N. The role of cytomegalovirus in angiogenesis. Virus Res. 157, 204-211 (2011).
172. Streblow, D. N. et al. Human cytomegalovirus chemokine receptor US28 induced smooth muscle cell migration is mediated by focal adhesion kinase and Src. J. Biol. Chem. 278, 50456-50465 (2003).
173. Melnychuk, R. M. et al. Human cytomegalovirus-encoded G protein-coupled receptor US28 mediates smooth muscle cell migration through Gα12. J. Virol. 78, 8382-8391 (2004).
174. Vomaske, J. et al. Differential ligand binding to a human cytomegalovirus chemokine receptor determines cell type-specific motility. PLoS Pathog. 5, e1000304 (2009).
175. Streblow, D. N. et al. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 99, 511-520 (1999).
176. Dumortier, J. et al. Human cytomegalovirus secretome contains factors that induce angiogenesis and wound healing. J. Virol. 82, 6524-6535 (2008).
177. McMaster, B. E., Schall, T. J., Penfold, M. E., Wright, J. J. and Dairaghi, D. J. Bicyclic compounds as inhibitors of chemokine binding to US28. Patent WO03018549 (2003).
178. McMaster, B. E., Schall, T. J., Penfold, M. E., Wright, J. J. and Dairaghi, D. J. Arylamines as inhibitors of chemokine binding to US28. Patent WO03020029 (2003).
179. Schall, T. J., McMaster, B. E. and Dairaghi, D. J. Modulators of US28. Patent WO0217900 (2002).
180. Schall, T. J., McMaster, B. E. and Dairaghi, D. J. Reagents and methods for the diagnosis of CMV dissemination. Patent WO0217969 (2002).
181. Kralj, A. et al. Identification of novel allosteric modulators for the G protein coupled US28 receptor of human cytomegalovirus. Bioorg. Med. Chem. Lett. 21, 5446-5450 (2011).
182. Kralj, A. et al. Development of flavonoid-based inverse agonists of the key signaling receptor US28 of human cytomegalovirus. J. Med. Chem. 56, 5019-5032 (2013).
183. Tan, Q. et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341, 1387-1390 (2013).
184. Jahnichen, S. et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV 1 replication and mobilize stem cells. Proc. Natl Acad. Sci. USA 107, 20565-20570 (2010).
185. Chang, D. K. et al. Humanization of an anti CCR4 antibody that kills cutaneous T cell lymphoma cells and abrogates suppression by T regulatory cells. Mol. Cancer Ther. 11, 2451-2461 (2012).
186. Rajagopal, S., Rajagopal, K. and Lefkowitz, R. J. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nature Rev. Drug Discov. 9, 373-386 (2010).
187. Vischer, H. F., Watts, A. O., Nijmeijer, S. and Leurs, R. G protein-coupled receptors: walking hand in hand, talking hand in hand? Br. J. Pharmacol. 163, 246-260 (2011).
188. Montaner, S., Kufareva, I., Abagyan, R. and Gutkind, J. S. Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases. Annu. Rev. Pharmacol. Toxicol. 53, 331-354 (2013).